

Ref: FOI/2023/8868

Date Received: 2nd May 2023

Response Due: 1st June 2023

Date: 16th June 2023

Dear Sir/Madam

You asked:

Q1. Could you please provide the numbers of patients treated by the rheumatology department (for any condition) in the last 3 months with the following drugs:

- **Abatacept [Orencia]**
16
- **Adalimumab [Humira]**
48
- **Adalimumab Biosimilars**
117
- **Apremilast [Otezla]**
5
- **Baricitinib [Olumiant]**
13
- **Certolizumab [Cimzia]**
23
- **Etanercept [Enbrel]**
32
- **Etanercept Biosimilars**
162
- **Filgotinib [Jyseleca]**
7
- **Golimumab [Simponi]**
21
- **Guselkumab [Tremfya]**
0

- **Infliximab [Remicade]**
<5
- **Infliximab Biosimilars**
<5
- **Ixekizumab [Taltz]**
<5
- **Risankizumab [Skyrizi]**
0
- **Rituximab [MabThera]**
<5
- **Rituximab Biosimilars**
29
- **Sarilumab [Kevzara]**
0
- **Secukinumab [Cosentyx]**
22
- **Tocilizumab [Ro Actemra]**
66
- **Tofacitinib [Xeljanz]**
<5
- **Upadacitinib [Rinvoq]**
<5
- **Ustekinumab [Stelara]**
<5

Q2. Could you please provide the numbers of patients treated for Axial Spondyloarthritis ONLY in the last 3 months with the following drugs.

- **Adalimumab [Humira]**
15
- **Adalimumab Biosimilars**
29
- **Certolizumab [Cimzia]**
5
- **Etanercept [Enbrel]**
9
- **Etanercept Biosimilars**
24
- **Golimumab [Simponi]**
<5
- **Infliximab [Remicade]**
0
- **Infliximab Biosimilars**
0
- **Ixekizumab [Taltz]**
0
- **Secukinumab [Cosentyx]**
10

- **Tofacitinib [Xeljanz]**
0
- **Upadacitinib [Rinvoq]**
0

Refusal Notice: Sec 40(2) Personal Information

The Trust has a policy of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,



Gary Masterman
Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office
Wycliffe House
Water Lane
Wilmslow
Cheshire, SK9 5AF

Helpline number: 0303 123 111